Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

Dr. Joshua Hare to Chair the Board

LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of heart failure.

The Medical Advisory Board will play an important supportive role in the design and oversight of the planned CDP-1050 Phase 2 clinical trial and assist in addressing regulatory and patients' welfare issues. It is composed of internationally recognized leaders in the field of heart failure; all of whom have extensive experience in the design and execution of clinical trials aimed at improved care of patients with heart failure.

CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.

The Medical Advisory Board is chaired by Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology, and Director of the Interdisciplinary Stem Cell Institute at University of Miami, Miller School of Medicine. He has pioneered the use of stem cell therapy to repair damaged hearts. Dr. Hare has authored and co-authored numerous peer-reviewed publications including a report on a multi-center clinical trial with oxypurinol, a modifier of cellular redox potential, in patients with symptomatic heart failure. He served as the principal investigator of that clinical trial. Dr. Hare has also authored a New England Journal of Medicine editorial on redox-nitric oxide balance in the cardiovascular system.

Other members of the Medical Advisory Board include:

Wilson S. Colucci, M.D., is the Thomas J. Ryan Professor of
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Hill, South Carolina (PRWEB) July 29, 2014 ... with teams of people where cell phone masts or other ... iPhones up to 100 feet away without the need for ... to target longer ranges. , The new app has launched ... of US homes are at very high risk of being ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... The first product launch from start-up Hurley Research ... What sets Droidles completely apart from other stand alone ... to communicate, share code with each other and evolve ... invention is the system,” said Hurley Research founder Jay ... their own, both physically and on the internet." Remote ...
(Date:7/29/2014)... July 29, 2014 The prestigious "Discovery ... Congress was recently awarded to Juliana Hillis and Kaylie ... for their project, “From an Egg, Everything: America’s First ... final entries for the National History Day program during ... historians and educators in Washington, D.C. , The growing ...
Breaking Biology Technology:DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... Epitomics, Inc. today announced that The Michael J. ... company to distribute a panel of LRRK2 monoclonal antibodies ... parties. Under a special arrangement the antibodies are being ... community to help advance LRRK2 therapeutic development efforts. The ...
... BASEL, Switzerland, Sept. 17 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEETS: ... Poulin as President and CEO. Mr Barry ... the Company,s direction during the summer of 2010, I ... in order to facilitate the transition process, and now ...
... 2010 bluebird bio (formerly Genetix Pharmaceuticals Inc.) an ... for severe genetic disorders, today announced publication in the ... data highlighting positive results of LentiGlobin gene therapy treatment ... disorder that is one of the most frequent inherited ...
Cached Biology Technology:Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp. 2Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study 2Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study 3
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... research from scientists at the University of Kent has ... cells are regulated a breakthrough that could have ... team from Kent,s School of Biosciences uncovered the mechanism ... cells known as actin filaments are ,fine-tuned, ... actin filaments appear to completely stable, providing a framework ...
(Date:7/29/2014)... rare disease it affects 1 in 100,000 people ... wall. While its cause remains unknown, a new study by ... University of Bonn in Germany and other European institutions confirms ... The study, published on 6 July in Nature Genetics ... , When we swallow, a sphincter in the lower esophagus ...
Breaking Biology News(10 mins):Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2Mysterious esophagus disease is autoimmune after all 2
... CHICAGO, Ill. (March 29, 2011)A medical device developed by ... a new paradigm for the detection, diagnosis and monitoring ... the Society of Interventional Radiology,s 36th Annual Scientific Meeting ... trauma is detected, identified and located using a simple ...
... global economy depends on marine transportation. But in addition ... stowaways that can cause huge problems for the environment ... will facilitate accurate screening of vessels for dangerous species ... in the journal Environmental Science & Technology . ...
... A novel supercomputing resource created by researchers at the ... San Diego, is allowing scientists to study evolutionary relationships ... times and without having to understand how to ... new resource, called the CIPRES (Cyberinfrastructure for Phylogenetic RESearch) ...
Cached Biology News:New device uses submarine technology to diagnose stroke quickly 2New device uses submarine technology to diagnose stroke quickly 3Smithsonian scientists help block ship-borne bioinvaders before they dock 2Smithsonian scientists help block ship-borne bioinvaders before they dock 3SDSC's CIPRES Gateway provides window to the past -- and fast 2SDSC's CIPRES Gateway provides window to the past -- and fast 3
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... solution. Cleaves a-(1-3)- and ... and glycoproteins. It is particularly efficient for ... pH must be neutral or above, for ... Unit Definition: One unit will hydrolyze ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
Biology Products: